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Abstract: Dalfampridine sustained-release (SR) is a time-release formulation of 4-aminopyridine, 
recently approved by the Food and Drug Administration to improve walking in patients with 
multiple sclerosis (MS). In Phase II trials, walking speed and lower extremity muscle strength was 
increased in patients with MS, but the increase in walking speed did not reach statistical significance. 
A responder analysis revealed that approximately 35% of treated patients had a statistically significant 
and clinically meaningful increase in walking speed. When treated responders were compared with 
treated nonresponders, walking speed significantly increased in the responder group, but not in the 
nonresponder or placebo groups. This result was duplicated in two larger Phase III trials. The optimal 
dose to maximize the risk–benefit ratio was 10 mg twice daily. Higher doses were associated with a 
greater risk of seizure, but no further improvement in walking speed or in the proportion of responders. 
Dalfampridine SR is eliminated by renal clearance and undergoes only limited metabolism (,10%). 
It is contraindicated in patients with moderate or severe renal insufficiency and in those with a history 
of seizures or epileptiform activity on electroencephalography. The development of time-released 
4-aminopyridine represents a major advance in symptomatic therapy for MS.
Keywords: dalfampridine SR, multiple sclerosis, ambulation, walking speed, clinical trials, 
safety
Core evidence clinical impact summary for dalfampridine sustained-release in 
multiple sclerosis
Outcome measure Evidence Implications
Disease-oriented 
evidence
Phase ii study First drug approved for the 
symptomatic 
management of multiple sclerosis
Phase iii studies Broad indication to improve walking in 
patients with MS
Small clinical trials with 
4-aminopyridine
This agent will be used widely and 
may be 
of substantial benefit to patients with 
MS 
Patient-oriented 
evidence
Responders showed 
improvements in the MS walking  
Scale and Subject Global index  
and Clinician Global index
Quality of life may be improved in 
responders
Economic evidence None
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Introduction
Multiple sclerosis (MS) affects over 400,000 people in the 
US and over a million people globally.1 In the last 15 years, 
significant advances have been made in the pharmacologic 
treatment of the inflammatory disease activity that partly 
defines the disease, but there has been little progress in the 
development of symptomatic therapies. This has been a 
significant unmet need in the treatment of MS.
Patients suffering from MS experience a variety of symp-
toms that negatively impact their quality of life. These include 
weakness, sensory loss, impaired coordination, cognitive 
dysfunction, pain, malaise, and bladder dysfunction, to name 
only a few.2 One of the challenges faced by clinicians treating 
MS is the amelioration of what its symptoms cause. This is 
often more challenging than bringing inflammatory disease 
activity under control. In one study, 64% of MS patients 
reported difficulty with walking, and in that group 78% 
reported that difficulty walking impaired their ability to work 
and 82% reported that it restricted their activities.3
In addition to the aforementioned symptoms, many 
patients have fatigability of strength. This is defined as a 
significant decrease in strength that occurs with repetitive 
movements. For example, if one lifts a 10 kg weight many 
times, the muscle will fatigue and the movement will become 
impossible to repeat. This phenomenon occurs normally, 
but in patients with MS it occurs much earlier, and is due to 
lesions within the central nervous system (CNS) that have 
not completely interrupted synaptic transmission. When high 
volumes of nerve impulses travel through damaged regions, 
action potentials slow and there is a dispersion of action 
potential volleys, leading to a decreased response.4 This is 
manifested as weakness when a motor pathway has been 
affected. This occurs quite commonly in patients with MS, 
so that even though ambulation may be initially normal, after 
the patient has walked a given distance, leg strength decreases 
and the patient must stop and rest. As a result, the develop-
ment of an agent to improve walking in patients with MS has 
been a significant unmet need in MS therapeutics.
Development of dalfampridine
4-Aminopyridine (4-AP) is a voltage-gated potassium chan-
nel blocker that results in an increase in the duration of the 
action potential. Potassium efflux out of the axon is the ionic 
mechanism that results in repolarization of the axon. This 
must occur before the axon can propagate another action 
potential. In MS, myelinated fibers are damaged, and when 
remyelination does occur, the sheath is thinner than those seen 
in undamaged fibers. The result is that there is an impedance 
mismatch and dispersal of action potentials within a volley 
traveling down the axon. This results in either a weakened 
signal when the volley of action potentials reaches its des-
tination or in outright conduction block. Clinically, this is 
manifested as weakness and in fatigability of strength. 4-AP 
increases the conduction of action potentials in demyelinated 
fibers, and in doing so, may result in improvement of strength. 
The administration of 4-AP may also result in increased 
neuronal excitability and in the potentiation of synaptic 
transmission.5 The latter may be due to increased release of 
neurotransmitter that occurs as a result of increased calcium 
influx at presynaptic terminals. Its action and toxicity could 
be due to either mechanism. As a result, 4-AP may lower the 
seizure threshold, and seizures have occurred in patients on 
compounded 4-AP.
Studies of 4-AP in a compounded formulation date back 
many years and have demonstrated significant benefits in 
MS patients. Several trials have demonstrated that some, but 
not all, patients experience improvement in motor function, 
ambulatory speed, and visual function.6–9 Others have dem-
onstrated an improvement in the fatigue severity scale and a 
decrease in the expanded Disability Status Scale (eDSS).9 
As a result of the positive results reported in these studies, 
4-AP has been widely used in clinical practice. Unfortunately, 
the reliability of the preparations produced in compounding 
pharmacies has been poor. As a result, the actual amount of 
4-AP in compounded product has varied widely, and this has 
led to unintentional overdose in some cases and inadequate 
amounts in other preparations.10,11 Further, serum levels of 
4-AP following administration of immediate-release 4-AP 
rise quite rapidly and peak at 1.2 hours.12 The serum level 
rapidly declines and this necessitates frequent dosing. The 
therapeutic index is quite narrow, which can lead to levels 
that are either too high or too low. Peak serum concentra-
tions following immediate-release 4-AP are high enough to 
increase the risk of seizure significantly.
A time-release formulation of 4-AP (dalfampridine) has 
been developed by Acorda Therapeutics and has recently 
been approved by the Food and Drug Administration (FDA) 
to improve walking in patients with MS. This review will 
summarize the data demonstrating the safety and efficacy 
of dalfampridine and discuss the scope of its use in the MS 
population.
Pharmacokinetics
Dalfampridine is highly lipid-soluble and readily penetrates 
the CNS, blocking potassium channels centrally and in the 
peripheral nervous system. Maximal serum concentration is Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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reached approximately three hours following oral adminis-
tration and the peak serum concentration is approximately 
20 ng/mL. Peak serum concentrations occur at 1.2 hours 
after administration of an immediate-release formulation and 
reach levels of 46 ng/mL.12 The half-life of dalfampridine 
sustained-release (SR) is 6.4 hours versus 3.7 hours for an 
immediate-release preparation. Twelve hours after dosing, 
the serum concentration of dalfampridine SR is approxi-
mately 12 ng/mL. The drug is almost completely eliminated 
within 24 hours.13–15 Bioavailability is 96%, and there is 
very little binding to plasma proteins (1%–3%). There is 
minimal metabolic transformation. Ninety percent of an 
administered dose is excreted in the urine as the parent com-
pound. A small amount is metabolized by CYP2e1, which 
results in two metabolites, neither of which has activity on 
potassium channels. In patients with renal insufficiency, peak 
dalfampridine SR concentrations are increased. In patients 
with mild renal impairment, as defined by a creatinine clear-
ance of 50–80 mL/min, peak concentrations were increased 
by 166%–200%. In those with severe impairment, as defined 
by a creatinine clearance of less than 30 mL/min, peak serum 
concentrations were increased by 175%–398%.13 Terminal 
half-life was also increased in patients with renal impairment. 
In those with mild, moderate, or severe impairment, half-life 
was 7.4 hours, 8.1 hours, and 14.3 hours, respectively. 
Therefore, its use in patients with moderate or severe renal 
impairment is contraindicated. In patients with mild renal 
insufficiency, serum concentrations could be increased and 
there is greater potential for adverse events. When the drug 
is taken with food, there is a modest (12%–17%) increase in 
peak serum concentration. Therefore, the drug may be taken 
with or without food.
Clinical trials
An early Phase II trial of dalfampridine SR in MS enrolled 
10 patients who were clinically stable, with motor deficits 
and an eDSS of 6.0 and 7.5.7 Patients were allowed to remain 
on other symptomatic medications and were randomized 
to receive dalfampridine SR 17.5 twice daily or placebo. 
Following the treatment period, patients were washed out 
for one week and then crossed over, so that the patients 
previously receiving dalfampridine SR were switched to 
placebo and vice versa. A number of outcome measures were 
used, including eDSS, grip strength, global impression, time 
to walk 8 m, and manual muscle strength testing. The only 
outcome measure that reached statistical significance was 
the timed walk. On that measure, nine of 10 patients had an 
increased walking speed (P = 0.02). Seven of 10 patients 
reported improved global impression scores on dalfampridine 
SR compared with placebo. There were no serious adverse 
events and no patient had a seizure. Minor adverse events 
included dizziness, insomnia, and paresthesias.
Of note is that subjective improvement and improvement 
on some outcome measures was related to the serum level. 
In patients whose serum level exceeded 60 ng/mL, there was 
improvement in timed walking, grip, and manual muscle 
strength testing. In addition, only patients whose serum 
concentrations exceeded 60 ng/mL reported subjective 
improvement.
Next came a further Phase II, double-blind, placebo-
controlled trial to determine the safety and efficacy of three 
doses of dalfampridine SR.16 In this trial, 206 patients were 
randomized to treatment with dalfampridine SR at doses of 
10 mg, 15 mg, or 20 mg twice daily. Patients had to have a 
timed 25-foot walk (T25FW) of 8–60 seconds and be aged 
18–70 years. The primary outcome measure was change in 
T25WF, and secondary outcome measures included the lower 
extremity manual muscle strength test, Ashworth scale, MS 
functional composite, and others. The trial utilized a two-
week run-in phase for dose escalation in the higher dose 
groups. Assessments were carried out at baseline, during the 
12-week stable dose phase, and after cessation of dosing.
The trial failed to demonstrate a statistically significant 
effect on the primary outcome measure, even though walking 
speed was faster for each of the treated groups compared 
with the placebo-treated group. There were improvements 
in lower extremity muscle strength, P = 0.018 for the 10 mg 
group and P = 0.003 for the 15 mg group. There were no 
statistically significant differences between groups for any 
of the other secondary outcome measures.
Following these analyses, a post hoc responder analysis 
was carried out. The mean increase in walking speed in the 
treated groups suggested that some, but not all, patients 
may have responded to treatment. The responder analysis 
was based on the criteria that a responder would have an 
improvement in walking speed while on drug that would 
reverse off drug. This was operationally defined as a patient 
whose walking speed on at least three visits during the 
double-blind treatment period was faster than the maximum 
speed achieved in the five off-treatment visits.
Using this criterion, the response rate was 8.5% in the 
placebo group, 35.3% in the 10 mg group, 36% in the 15 mg 
group, and 38.6% in the 20 mg group. These differences all 
achieved statistical significance. In the dalfampridine SR 
treated responder groups, walking speed increased from 25% 
to 29%. This degree of improvement is considered clinically Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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significant.17,18 Also of note is that the change in walking 
speed in the responder groups treated with dalfampridine 
SR was maintained over the 12-week treatment period. 
In the responder groups, there were statistically significant 
improvements in the MS Walking Scale (P = 0.020) and on 
the Subject Global Index (P = 0.004). Unfortunately, there 
was no association between responder status and any demo-
graphic variable. Neither age, eDSS, MS subtype, nor any 
other variable predicted responder status.
Dalfampridine SR was generally well tolerated. There 
was no difference in the overall frequency of adverse events 
between the 10 mg dose group and placebo. In general, 
there was an increased risk of serious adverse events in the 
15 mg and 20 mg dose groups. In the 15 mg dose group, 8% 
experienced serious adverse events and, in the 20 mg dose 
group, 12% experienced serious adverse events. In the 15 mg 
group, one patient discontinued treatment due to nausea and 
dizziness. In the 20 mg dose group, five patients discontinued 
treatment. Two of those patients experienced seizures, one 
had abnormal coordination, one had chest pain and headache, 
and one other had blurred vision, balance disorder, headache, 
and paresthesia.
The results of this study suggested that a subset of MS 
patients with motor dysfunction and impaired walking 
responded to dalfampridine SR. Importantly, another group 
indistinguishable on the basis of clinical characteristics did 
not respond. Overall, safety and tolerability appeared quite 
good in the 10 mg dose group and the clinical benefits in the 
responder group were enhanced by the use of higher doses 
which posed a greater risk of adverse events. Therefore, 
further Phase III trials used dalfampridine SR at 10 mg twice 
daily and included a prospective responder analysis.
The next trial to determine efficacy was a randomized, 
multicenter, double-blind, Phase III trial in 296 patients with 
MS.17 Inclusion criteria included being aged 18–70 years, with 
any MS subtype, and a T25FW of 8–45 seconds at screening. 
Those with a history of seizures or epileptiform activity on 
a screening electroencephalogram (eeG) were excluded 
from the study. Patients meeting the inclusion criteria were 
randomized to placebo or dalfampridine SR 10 mg twice daily. 
The primary outcome measure was response to treatment, 
using the T25TW as the determinant of response. Secondary 
outcome measures included the Ashworth scale and lower 
extremity manual muscle strength test. The MS Walking Scale, 
Subject Global Impression, and Clinician Global Impression 
were also employed as tertiary outcome measures.
Using the responder analysis, there were significantly more 
responders in the dalfampridine SR group than in the placebo 
group (35% versus 8%; P , 0.0001). The average change 
from baseline in walking speed in the responder group was 
25.2%. This increase was maintained over the 14-week treat-
ment period and, when the drug was discontinued, walking 
speed returned to rates observed at screening, suggesting that 
the responder analysis accurately captured those who dem-
onstrated a beneficial effect. effects on secondary outcome 
measures also reached statistical significance. Responders had 
decreased scores on the MS Walking Scale (−6.84) compared 
with nonresponders (0.05; P = 0.0002. Significant differences 
were reported favoring dalfampridine SR responders on the 
Subject Global Impression, Clinician Global Impression, and 
lower extremity muscle strength test as well.
Safety and tolerability in this Phase III trial was con-
sistent with the results of the Phase II study showing good 
tolerability and an acceptable safety profile. eleven (5%) 
of patients in the dalfampridine SR group discontinued the 
study due to adverse events. Two serious adverse events in 
the dalfampridine SR group were considered to be possibly 
drug-related. The first was a patient with worsening anxiety 
on treatment. When treatment was withheld, this resolved 
but reappeared when treatment was started again. The second 
patient experienced a seizure in the context of pneumonia 
and a urinary tract infection. Milder adverse events more 
common in the dalfampridine SR group were also consistent 
with adverse events seen in the Phase II trial, and included 
dizziness, nausea, insomnia, fatigue, and impaired balance.
The results of this trial confirm those of the Phase II 
study and suggest that roughly 35% of MS patients with 
fixed motor weakness and gait impairment may respond to 
and benefit from dalfampridine SR. No unexpected adverse 
events occurred during the course of the trial, suggesting an 
acceptable risk-benefit ratio.
A second Phase III trial intended to provide supporting 
data for registration has been completed.19 This trial enrolled 
239 patients with MS. Inclusion criteria were similar to the 
first Phase III trial. Patients with MS and aged 18–70 years 
were enrolled. Patients must have had motor weakness and 
gait impairment with a T25FW of 8–45 seconds. Patients 
were excluded if they had a history of seizures or epilepti-
form activity on eeG. After the screening visit, patients were 
randomized to placebo or dalfampridine SR, and underwent 
a two-week run-in phase prior to a nine-week treatment 
phase. Following the end of the nine-week treatment phase, 
the drug was discontinued and patients were reassessed two 
weeks after cessation of treatment.
The primary outcome measure in this trial was the 
proportion of patients responding to treatment. A treatment Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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responder was defined as a patient who had a faster walking 
speed on three out of four treatment visits than any maximum 
speed during five off-treatment visits. Off-treatment visits 
were those at screening, during the run-in period, and after 
treatment cessation. In this fashion, a fairly stringent criterion 
for treatment response was defined.
The patient population consisted of all MS subtypes. 
Approximately 33% were relapsing–remitting, 8%–17% 
were primary progressive, 47%–51% were secondarily 
progressive, and 2%–4% were progressive relapsing. eDSS 
scores ranged from 1.5 to 7.0. Approximately 43% of the 
patients treated with dalfampridine SR were classified as 
responders compared with only 9% percent of the placebo 
group. This was similar to the results reported in the earlier 
Phase III study, and suggested that dalfampridine SR may 
bring about a clinically significant improvement in walk-
ing speed and strength in a substantial portion of the MS 
patient population. In the dalfampridine SR responders, 
walking speed increased by about 25% compared with 
placebo and with nonresponders. Of interest, the patients 
who did not respond had walking speeds quite comparable 
with those of placebo-treated patients. In addition, walking 
speed was measured at intervals following the last dose, 
and this analysis showed that 12 hours after the last dose 
of dalfampridine SR walking speed decreased, supporting 
twice-daily dosing. Responders also had significant improve-
ments in MS Walking Scale 12 hours after the last dose of 
dalfampridine SR.
A pooled analysis of all patients enrolled in the Phase 
II trial and both Phase III dalfampridine SR trials showed 
statistically significant improvements in walking speed in 
an analysis that compared placebo with treated patients and 
did not distinguish between responders and nonresponders.20 
The average improvement in walking speed in the pooled 
data set was 13.4%. In total, 31.5% showed at least a 20% 
improvement in walking speed and 15.5% showed a 30% 
increase in walking speed. Adverse events in the pooled sample 
population were similar to those reported in earlier studies, and 
included an increased frequency of asthenia, fatigue, dizziness, 
headache, nausea, and impaired balance. Of note is that there 
was also an increased risk of urinary tract infection (14.5% in 
dalfampridine SR versus 9.2% in placebo).
Use of dalfampridine  
SR in clinical practice
Dalfampridine SR was approved by the FDA on the basis of 
the studies reviewed in this paper. It was given a very broad 
indication, ie, “to improve walking in patients with MS”.   
The FDA did not restrict its use to those with an eDSS of 
2.5–7.0 nor to patients with a T25FW of 8–45 seconds. This is 
the first agent ever to be approved for the symptomatic manage-
ment of MS (see Table 1). Its use could benefit 30%–40% of 
the MS population. Unfortunately, there are no predictors of a 
positive response to dalfampridine SR. Therefore, its benefit 
or lack thereof will have to be determined empirically in each 
patient. If patients perceive benefit, they will continue to take the 
drug and, if not, they will likely discontinue it on their own.
Of note is that dalfampridine SR could be useful to 
improve other mobility function in MS. It is possible, 
although there are no data to support it, that patients with 
limited upper extremity function could benefit. Likewise, 
it is also possible that patients with limited ability to transfer 
could benefit from treatment with dalfampridine SR. This 
will have to be determined in Phase IV studies.
Dalfampridine SR is contraindicated in patients with a 
history of seizures and may increase the risk of seizures. 
The increased risk of seizures at 10 mg twice daily was 
minimal but the possibility remains. It is also contraindicated 
in patients with moderate and severe renal impairment, 
and its use in patients with mild renal impairment should 
be undertaken with caution. Patients must also be warned 
that taking additional doses of dalfampridine SR will not 
bring about further benefit and could increase the risk of   
seizures.
The introduction of dalfampridine SR represents an 
important improvement in the care of MS patients. It is the 
first drug approved by the FDA for the symptomatic man-
agement of MS patients, and has the capability to improve 
function and quality of life in those with motor weakness 
and ambulatory impairment.
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